This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Obagi Medical Products Expands Partnership with Japan-Based Rohto Pharmaceutical Co., Ltd. 2008-12-16 10:28 ET - News Release Also News Release (U-OMPI) OBAGI MEDICAL PRODUCTS INC
- ELASTIderm® to be Sold in Japan Under a Licensing Agreement with
Rohto
- Companies to Collaborate to Develop Scientifically Based Skin Care
Products At Rohto’s State-of-the-Art Scientific Facilities
LONG BEACH, Calif. -- (Business Wire)
Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical
aesthetic and therapeutic skin health systems, today announced an
expansion of its relationship to Rohto Pharmaceutical Co., Ltd.,
(TYO:4527) a leading brand manufacturer of over-the-counter products,
and Obagi’s leading marketing and distribution partner, in Japan.
Together, the Companies will launch a series of products with
ELASTIderm™’s technology into consumer sales and distribution channels
in Japan, including premium retail distribution channels, as well as
jointly develop other scientifically based skin care products for the
Japanese market.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page